Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says
Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Definium Therapeutics announced positive topline results from its Phase 3 Emerge study of the DT120 orally disintegrating tablet for major depressive disorder. The LSD-based therapy demonstrated strong antidepressant effects and profound efficacy, which led to a surge in the company's stock price.
Epilogue added 7d ago, after coverage quieted.
The brief
Definium Therapeutics has reported positive results from a Phase 3 trial of its LSD-based depression treatment, DT120. The company's CEO described the data as the 'best ever seen' in such a trial.
Coverage from outlets including BioSpace, Yahoo Finance, and Reuters emphasizes the strong efficacy of the drug in treating major depressive disorder. Business Wire reports that Definium will discuss the topline results from the Phase 3 Emerge study.
The next steps involve further analysis of the trial data and potential regulatory submissions. Coverage does not yet specify the timeline for these processes.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 19d ago.
Quick answers
What is the name of Definium's LSD-based depression treatment?
The treatment is called DT120.
Which phase of trial has DT120 completed?
DT120 has completed a Phase 3 trial.
What is the stock ticker for Definium Therapeutics?
The stock ticker for Definium Therapeutics is DFTX.
Coverage (11)
- Definium’s LSD-based therapy elicits ‘profound’ efficacy in Phase 3 depression trial BioSpace · 22d ago
- Definium Therapeutics (DFTX) Hits New High on Impressive Drug Candidate Trial Yahoo Finance · 22d ago
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect Psychedelic Alpha · 22d ago
- 🔎 Under the Radar: Definium Shares Propelled by Strong Psychedelic Results WSJ · 22d ago
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder Business Wire · 22d ago
- Definium's LSD-based drug scores win in key major depressive disorder study FirstWord Pharma · 22d ago
- Definium LSD therapy helped patients with major depression in late-stage trial statnews.com · 22d ago
- DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results Yahoo Finance · 22d ago
- Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026 Business Wire · 22d ago
- Definium's LSD-based depression pill delivers strong late-stage results, shares surge Reuters · 22d ago
- Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says Fierce Biotech · 22d ago
Topics
Related trends
Japanese scientists identify neural mechanism that may explain why we dislike people
5 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Compass says depression drug has long-lasting benefits
Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer's Phase 3 trial for the lung cancer drug Sigvotatug Vedotin failed to meet its primary endpoint for survival.